Skip to main content
Sign In

Search

Search for a Specific Type of Clinical Trial
Note: This page will take a moment to download because of the quantity of trials.

Feedback

Did you have problems using this page? Please fill out our Feedback Form

Clinical Trials

Volunteer to Be Part of a Research Study

Page through all School of Medicine clinical and research trials below. There are two categories:

  • Detailed Trial Descriptions, submitted by researchers, includes trial specifics and contact information.

  • Additional Clinical Trials, which include basic study details. To contact the researcher either Google the PI (primary investigator) name or use our campus directory.

If you are a researcher seeking volunteers and your study is not posted, please
submit your Web ad here.
  

Detailed Trial Descriptions

 Results From Research and Clinical Trials : Selected site
Data pager
<
>
Page Size
PageSizeComboBox
select
 |  Displaying page 1 of 5, items 1 to 30 of 122.
TitleStudy GoalsEligibility CriteriaContact Information
Data pager
<
>
Page Size
PageSizeComboBox
select
 |  Displaying page 1 of 5, items 1 to 30 of 122.
Do you have Parkinson's Disease? 11-1237
To explore the effects of different doses of endurance exercise in people with PD.​
Persons 40-80 who have been diagnosed with Parkinson's Disease and are not yet taking medication or plant to start medication within the next 6 months. You must be willing to begin the exercise program immediately or after a delay of 6 months and willing to do aerobic exercise on a treadmill.
PI: Schenkman, Margaret
  • 720-848-6376
  • Toby.Wellington@ucdenver.edu
Do you have Atopic Dermatitis (Eczema)? HS-2581
To study eczema
Males and Females between 3 and 80 who have atopic dermatitis or males and females between 8 months and 80 who have a history of, or an active case of eczema hereticum (wide-spread herpes skin infection along with atopic dermatitis.
PI: Leung, Donald
  • 303-398-1409
  • taylorp@njhealth.org
Better Control of Type 2 Diabetes May Decrease Your Risk for Cardiovascular Disease. 10-0644
To look at the use of an extended release formula of Exenatide compared to a placebo to maintain normal glucose levels. Ultimately to see better control of diabetes and a decrease in cardiovascular disease events.​
Person 18+ with Type 2 Diabetes and take no more than 2 diabetes medications with stale doses for the last 3 months. Must not have a planned or anticipated revascularization procedure, but may have a history of cardiovascular disease and must see your primary care physician at least twice a year.
PI: Rasouli, Neda
  • 303-399-8020 X2059
  • chantal.underkofler@ucdenver.edu
Type 2 Diabetes and Exercise Research Study 10-1393
To research the effects of an investigational drug on exercise capacity and blood vessel function​.​
Person 30-60 with Type 2 diabetes who exercise vigorously less than one hour per week and have normal blood pressure. Must not have smoked for at least one year and have a BMI between 25-39.9.
PI: Schauer, Irene
  • 720-848-6690
  • Ellen.Lyon@ucdenver.edu
Are you a Non-smoking Adult between the ages of 45 and 85? HS-1883a
We are interested in learning more about smoking related lung disease, and need healthy non-smoking participants.
45-85 years old Non-Hispanic White or African American No smoking history No evidence of lung disease
PI: Bowler, Russ
  • 303-270-2566
  • FratelliC@NJHealth.org
Alterations in Lung Microbiome in Acute and Chronic HIV Infection 09-0898
This is a prospective, observational cohort study. Three groups (A1, A2, and B) will be enrolled in parallel.
-Men and women >/= 18 years. -Willing to follow all research requirements -Willing to provide written informed consent -Group A1- acute HIV infection defined as a high risk HIV exposure within the prior 30 days, or recent HIV-1 seroconversion defined as those with a high risk HIV-1 exposure -Group A2- healthy controls: HIV-1 seronegative with no high risk HIV-1 exposure in the prior 30 days and no chronic medical illness -Group B- HIV-1 infection diagnosed by a previous positive antibody or PCR test have been recommended to initiate HAART by their health care provider You should not be in this study if you are a pregnant or planning to become pregnant.
PI: Campbell, Thomas
  • 303-724-0762
  • christine.griesmer@ucdenver.edu
Volunteers needed to Participate in a Research Study about Rheumatoid Arthritis 01-675
The purpose of this study is to learn more about how rheumatoid arthritis develops by studying people who do not have rheumatoid arthritis. Your participation in this study will help us determine if certain genetic and environmental factors affect the chances of developing RA-related autoantibodies in absence of rheumatoid arthritis.
You may be eligible to participate in the study if: -You are at least 40 years old -You do NOT have Rheumatoid Arthritis (RA)
PI: Norris, Jill
  • 303-724-7510
  • Marie.Feser@ucdenver.edu
Restoring Insulin Secretion (RISE) 13-0122
The Children’s Hospital Colorado Clinical Translational Research Center and the National Institutes of Health are conducting a study. This study is aimed at testing whether early treatment is beneficial to kids with early type 2 diabetes and kids at high risk of diabetes.
10-19 years of age, Pubertal, Overweight, Fasting glucose: >90 mg/dl; Impaired glucose tolerance: >140 mg/dl; Pre-diabetes or diagnosed with diabetes for less than 6 months; Metformin
PI: Nadeau, Kristen
  • Susan Gross
  • susan.gross@childrenscolorado.edu
Do You Smoke? 12-0181
To figure out how these lung substances work in people who drink too much alcohol, who usually smoke, compared to those who do not drink heavily, but who smoke.
Smoking and nonsmoking males
PI: Burnham, Ellen
  • 303-724-6081
  • Carrie.Higgins@ucdenver.edu
Parents or Legal Guardians of Children with Disabilities 12-1664
Assistive Technology Partners, University of Colorado, Anschutz Medical Campus, is performing a study investigating the impact Socially Assistive Robotics has on motor, communication and cognitive skills of children with disabilities.
Children between the ages of 18 months to 5 years of age Have Significant motor and communication disabilities/delays NOT been diagnosed with blindness or deafness They are without a seizure disorder or with a well-controlled seizure disorder They have been on stable medication regime for the past 12 weeks, if they are currently taking medication.
PI: Sandstrum, Jim
  • 303-315-1287
  • Jim.Sandstrum@ucdenver.edu
The Influence of Couples' Conversation on the Heart 13-2188
The purpose of the study is to examine the influence that conversations between married couples have on the functioning of the heart.
Married Christian couples who: • Have been married for at least 1 yr. • Both believe in prayer. • Are not currently taking heart medications. • Do not have heart problems. • Are not pregnant.
PI: Grigsby, Megan
  • 303-556-6020
  • couplesandheartstudy@gmail.com
Help Us Learn About Schizophrenia! 12-1186
Help us learn more about a new drug that may improve thinking and concentration in people with schizophrenia.
We are looking for: Male and female adults who smoke 18-50 years old No previous or current mental illness No drug use Willing to use nicotine patch during study hospital visit If female, willing to use birth control during the study
PI: Freedman, Robert
  • 303-724-6214 or 303-724-7373
  • psypharmresearch@ucdenver.edu
Do you use just a rescue inhaler for asthma treatment? 29167/38
Researchers are studying an investigational medication for the treatment of asthma in adults.
Qualifications include: 18-75 years old with asthma Use only a rescue inhaler for asthma treatment
PI: Katial, Rohit
  • 303-398-1966
  • currierh@njhealth.org
Research Trial Evaluating a New Drug in Psoriasis: Now Enrolling 14-1692
The study will evaluate an investigational drug compared to a currently approved psoriasis medication. Your participation will provide valuable information to researchers seeking new and improved therapies. You will be given either Humira, placebo, or the investigational drug for up to 28 weeks, after which you may be switched over to the active drug depending on your response.
You may be eligible to participate if 18 years of age or older and have been diagnosed with moderate to severe plaque-type psoriasis for at least 6 months.
PI: Armstrong, April
  • 720-848-3607
  • psoriasiscolorado@ucdenver.edu
DO YOU LIKE TO EAT? HEALTHY MEN needed to participate in a research study 14-2411
Research whether age affects how fat tissue responds to 1 week of overfeeding
Men who are age 25-40 yr or 55-75 yr overweight or mildly obese sedentary to moderately active non-smokers
PI: Van Pelt, Rachael
  • 720.848.6418
  • Tracy.swibas@ucdenver.edu
Participants with Chronic Kidney Disease and Vitamin D Deficiency Needed for a Research Study 11-0521
This study will examine whether nutritional or active vitamin D supplementation will improve blood vessel function​.
Person 18-80 with chronic kidney disease stage 3B or 4 (estimated GFR 44-15 m;/min) with a vitamin D deficiency or insufficiency.  Women must not be pregnant or breastfeeding.
PI: Kendrick, Jessica
  • 303-724-2275
  • Emily.Decker@ucdenver.edu
Trouble Sleeping? HS-2655
Study the effects of two different study drugs, one or two non-drug interventions and/or a combination of both to treat insomnia.
Persons 21+ who have trouble falling or staying asleep at night.
PI: Edinger, Jack
  • 303-398-1938
  • DepewA@njhealth.org
Give Us a Hand 12-1084
To better understand Multiple Sclerosis in children and teens.
Between the ages of 3-20 AND have Multiple Sclerosis diagnosed before 18 OR Do not have MS
PI: Schreiner, Teri
  • 303-724-3635
  • kathryn.connelly@ucdenver.edu
Are you an African American with asthma? HS-2805
 We are studying why some African American people have trouble with their asthma despite taking asthma medications.
 Children age 5-17 and non-smoking Adults age18 and older who have asthma symptoms despite asthma treatment • African American ancestry (have at least one    African American grandparent)
PI: Wechsler, MD, Michael
  • 303-398-1443
  • sundstromd@njhealth.org
Peanut and Tree-Nut Allergy Research Study 13-2102
The purpose of this study is to determine how the body's immune system interacts with nuts and other foods to cause allergic reaction.
6-75 years of age. Have a diagnosis of peanut and/or tree-nut allergy made by either skin test or blood tests. Have no known peanut and/or tree-nut allergy.
PI: Dreskin, Stephen
  • 303-724-7193
  • Spodra.Eglite@ucdenver.edu
Research about the Effect of Carbamazepine medication on the Etonogestrel Contraceptive Implant (Implanon®/Nexplanon®) 14-0584
Do you currently have a birth control implant (Implanon®/ Nexplanon®) and are interested in participating in a research study to better understand the effects of certain medication on the implant?
Women ages 18-45 who have had a birth control implant 1 to 3 years • Do not take any medications that are known to effect liver enzymes • Be willing to abstain during the study period or use a secondary form of non-hormonal contraception • Have baseline systolic blood pressure
PI: Lazorwitz, Aaron
  • 303-724-8482
  • maryke.swartz@ucdenver.edu
Do you have human growth hormone (hGH) deficiency? 13-2629
Primary: To demonstrate a clinical superiority of MOD-4023 over placebo in terms of decrease in Fat Mass (FM) in adult subjects with Growth Hormone Deficiency Secondary a. To determine the efficacy of MOD-4023 over placebo in other body composition variables (such as lean body mass and waist-to-hip ratio) b. To evaluate the safety and tolerability of MOD-4023 over placebo in adult subjects with GHD c. To determine the IGF-I and IGFBP-3 serum levels
Adult men and women aged 23 to 70 years of age diagnosed with either adult or childhood onset growth hormone deficiency (GHD).
PI: Wierman, Margaret
  • 720-848-7710
  • Shannon.Moore@ucdenver.edu
Are you a parent of a child with a developmental disability and willing to contribute to a research project to increase awareness and understanding? 14-1287
The purpose of this study is to gain knowledge on the topic of everyday stressors that affect the lives of children with developmental disabilities, as well as their parents/caregivers
Are you a parent of a child with a developmental disability and willing to contribute to a research project to increase awareness and understanding?
PI: Benson, Brenna
  • (303) 520-7346
  • brenna.benson@ucdenver.edu
Healthy Female Adults Needed!!! 07-0816
For brain imaging research study on how the brain works with we taste sweets. Your participation could help us to develop treatments and preventive measures for anorexia nervosa and obesity
Healthy females 22 to 29 who are right-handed, free of medication with no serious medical conditions, permanent metal implants or braces/retainers, and are at a healthy body weight.
PI: Frank, Guido
  • 720-777-4026
  • imaging.research@childrenscolorado.org
Do you have an egg allergy? HS-2764
To see if taking Baked Egg Therapy vs. Oral Immunotherapy may help egg-allergic children tolerate eggs.
males and females 3 to 16 years old, with documented egg allergy, ability to make regular visits to National Jewish Health for up to 2 years.
PI: Leung, Donald
  • 303-398-1618
  • ReamesR@NJHealth.org
State of Slim Study Examining Soy 14-1666
The CU Anschutz Health and Wellness Center is seeking volunteers for a new weight loss research study looking at the role of soy protein in weight loss and weight maintenance. The study will last approximately 12 months. Participants will participate in a 16-week State of Slim weight loss program at no charge and receive free soy products or monetary stipends to be used to purchase State of Slim-friendly protein products. Participants will receive DEXA body composition scans, lab work and wellness assessments at no charge.
Are between 18 – 55 years old Are overweight or obese (a BMI ≥27 and ≤40) - Check your BMI at: http://www.nhlbi.nih.gov/health/educational/lose_wt/BMI/bmicalc.htm Are willing to participate in weekly group weight loss classes for 16 weeks and attend five study visits over a 12 month period at the Anschutz Medical Campus Are not vegetarian Are not taking medications for cholesterol Are not diabetic
PI: Hill Ph.D, James
  • 303-724-9198
  • hannah.k.nelson@ucdenver.edu
Randomized Trial to Prevent Vascular Events in HIV (REPRIEVE) 15-0023
Pitavastatin is a statin that along with diet is used for the treatment of high cholesterol. It also lowers triglyceride levels in the blood. The main purpose of this clinical trial is to see if pitavastatin can prevent heart disease and heart disease related deaths in people with HIV infection who are taking HIV medications.
This study lasts about 6 years (21 visits) and you may be eligible if: • You have HIV and are between the ages of 40 and 75. • You have been on antiretroviral therapy (ART) for at least 6 months. • You have a CD4+ cell count > 100. • You have no history of cardiovascular disease (history of heart attack or stroke, etc.). • You are not currently using a statin drug.
PI: Campbell, MD, Thomas
  • 303-724-0712
  • graham.ray@ucdenver.edu
We are looking for Healthy Men and Women to participate in a research study to determine how Exercise Impacts Fat Metabolism During Sleep 13-0359
The University of Colorado Anschutz Medical Campus is recruiting healthy men and women to participate in a research study investigating how exercise performed during the day impacts hormones and metabolism during sleep.  Adults spend about one-third of their lives sleeping yet little is known about metabolism during this period or how day time exercise influences sleeping metabolism.  Learning more about sleeping metabolism will improve our understanding of how the body regulates body weight.
This research study is looking for healthy men and women aged 20 to 35 years, who have a BMI < 30, exercise less than 3 days per week, and have a regular sleep schedule.
PI: Rynders, Corey
  • 720-848-6461
  • corey.rynders@ucdenver.edu
Are you Interested in Being in a Weight Loss Research Study? 13-1550
Volunteers needed for a research study to determine the best time to begin exercise within a lifestyle weight loss program.
• Be a man or woman between 18 and 55 years old • Be generally healthy without diabetes or heart disease • Be a non-smoker • Not currently exercising regularly • Have a BMI between 28 and 40 kg/m2 In order to enroll all participants must meet specific criteria. The criteria listed above is only a partial list of all the requirements to participate in this research study. Only a clinical research staff member can determine eligibility.
PI: Catenacci, Victoria
  • 303-724-9098
  • knbing@gmail.com
Are you thinking about getting an IUD? 15-0413
The University of Colorado School of Medicine’s Department of OB/GYN is seeking volunteers for a research study of a new copper intrauterine device.
Eligible participants must: • Be generally healthy • Be interested in using an IUD • Be 18-40 years old • Have regular menstrual cycles
PI: Teal, Stephanie
  • 303-724-5284
  • Cricket.McHugh@ucdenver.edu

​Additional Clinical Trails

 Results From Research : Selected site
Data pager
<
>
Page Size
PageSizeComboBox
select
 |  Displaying page 1 of 24, items 1 to 30 of 706.
Protocol TitlePI NameInstitution Number
Data pager
<
>
Page Size
PageSizeComboBox
select
 |  Displaying page 1 of 24, items 1 to 30 of 706.
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study Assessing the Effect of Gelesis100 on Body Weight in Overweight and Obese Subjects with and without Type 2 Diabetes. Sponsor Protocol No. G-04. WIRB Protocol No. 20150046
Hill, James14-0383
A Randomized Phase 3 Open Label Study of Nivolumab versus Bevacizumab and a Safety Study of Nivolumab or Nivolumab in Combination with Ipilimumab in Adult Subjects with Recurrent Glioblastoma (GBM)(CheckMate 143: CHECKpoint pathway and nivoluMAb clinical Trial Evaluation 143). Sponsor Protocol No. CA209143. WIRB Protocol No. 20140894
Damek, Denise14-0518
A Phase 3 Randomized, Placebo-Controlled Trial of Carboplatin and Paclitaxel With or Without the PARP Inhibitor Veliparib (ABT-888) in HER2-Negative Metastatic or Locally Advanced Unresectable BRCA-Associated Breast Cancer Sponsor Protocol No. M12-914 WIRB Protocol No. 20141072
Borges, Virginia14-0799
PROspective Study of the IMPACT of Decipher® Prostate Cancer Classifier on Physician and Patient Treatment Consideration and Decisions following Radical Prostatectomy [PRO-IMPACT] Sponsor Protocol No. CU004 WIRB Protocol No. 20142208
Maroni, Paul14-0910
A Double-masked, Placebo-controlled Study with Open-Label Period to Evaluate the Efficacy and Safety of MEDI-551 in Adult Subjects with Neuromyelitis Optica and Neuromyelitis Optica Spectrum Disorders Sponsor Protocol No. CD-IA-MEDI-551-1155 WIRB Protocol No. 20142285
Bennett, Jeffrey14-0926
CEP292- A Performance Evaluation of the Enlite 3 Sensor to Support a Full 168 hours (7days) of Use. Sponsor Protocol No. CEP292/Z25/B. WIRB Protocol No. 20140632
Slover, Robert14-1039
A PHASE 2, MULTI-CENTER, MULTI-NATIONAL, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PARALLEL-GROUP CLINICAL TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF RPC4046 IN ADULT SUBJECTS WITH EOSINOPHILIC ESOPHAGITIS. Sponsor Protocol No. RPC02-201. WIRB Protocol No. 20140555
Menard-Katcher, Paul14-1285
A Phase 4 Multicenter, Open-Label, Single Arm Study to Evaluate Switching from BRACET/Gilenya® to Natalizumab in Subjects with Relapsing Forms of Multiple Sclerosis (MS). Sponsor Protocol No. 101MS409. WIRB Protocol No. 20141062
Alvarez, Enrique14-1295
A Clinical Outcomes Study to Compare the Incidence of Major Adverse Cardiovascular Events in Subjects Presenting with Acute Coronary Syndrome Treated with Losmapimod Compared to Placebo. Sponsor Protocol No. PM1116197. WIRB Protocol No. 20141040
Krantz, Mori14-1331
A Double-Blind, Placebo-Controlled, Randomized-Withdrawal, Multicenter Study of the Efficacy and Safety of Xyrem with an Open- Label Pharmacokinetic Evaluation and Safety Extension in Pediatric Subjects with Narcolepsy with Cataplexy Sponsor Protocol No. 13-005 WIRB Protocol No. 20141141
Halbower, Ann14-1333
A Randomized, Double-blind, Placebo-controlled, Ascending Multiple-Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AMG 282 in Healthy Subjects and Subjects with Chronic Rhinosinusitis with Nasal Polyps. Sponsor Protocol No. 20110236. WIRB Protocol No. 20150667
Kingdom, Todd14-1371
An Open-label, Non-randomised, Multicentre, Comparative, Phase I Study to Determine the Pharmacokinetics, Safety and Tolerability of AZD9291 following a Single Oral Dose to Patients with Advanced Solid Tumours and Normal Hepatic Function or Mild or Moderate Hepatic Impairment Sponsor Protocol No. D5160C00008 WIRB Protocol No. 20142209
O'Bryant, Cindy14-1390
A PHASE 2, MULTI-CENTER, MULTI-NATIONAL, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PARALLEL-GROUP CLINICAL TRIAL TO EVALUATE THE EFFICACY AND SAFET Sponsor Protocol No. RPC02-201 WIRB Protocol No. 20140555
Fleischer, David14-1399
BOTOX® Treatment in Pediatric Lower Limb Spasticity: Double-blind Study Sponsor Protocol No. 191622-111 WIRB Protocol No. 20132162
Biffl, Susan14-1404
BOTOX® Treatment in Pediatric Lower Limb Spasticity: Open-label Study Protocol No. 191622-112 WIRB Protocol No. 20132135
Biffl, Susan14-1405
An Open-Label Study to Evaluate the Safety, Efficacy and Pharmacokinetics of Ombitasvir/ ABT-450/Ritonavir (Ombitasvir/ABT-450/r) and Dasabuvir Co-administered with Sofosbuvir (SOF) With and Without Ribavirin (RBV) in Direct-Acting Antiviral Agent (DAA) Treatment-Experienced Adults With Genotype 1 Chronic Hepatitis C Virus (HCV) Infection. Sponsor Protocol No. M14-224. WIRB Protocol No. 20142269
Everson, Greg14-1435
A 6-month safety and benefit study of inhaled fluticasone propionate/salmeterol combination versus inhaled fluticasone propionate in the treatment of 6,200 pediatric subjects 4-11 years old with persistent asthma. Sponsor Protocol No. SAS115358. WIRB Protocol No. 20111924
Anderson, William14-1445
A PHASE IB/II STUDY EVALUATING THE SAFETY, TOLERABILITY AND ANTI-TUMOR ACTIVITY OF POLATUZUMAB VEDOTIN (DCDS4501A) IN COMBINATION WITH RITUXIMAB (R) OR OBINUTUZUMAB (G) PLUS BENDAMUSTINE (B) IN RELAPSED OR REFRACTORY FOLLICULAR OR DIFFUSE LARGE B-CELL LYMPHOMA Sponsor Protocol No. GO29365 WIRB Protocol No. 20141475
Gutman, Jonathan14-1455
A Phase II Randomized, Double-Blind, Placebo-Controlled Trial of Radium-223 Dichloride Versus Placebo When Administered to Metastatic HER2 Negative Hormone Receptor Positive Breast Cancer Subjects with Bone Metastases Treated with Hormonal Treatment Background Therapy Sponsor Protocol No. BAY 88-8223 / 16298 WIRB Protocol No. 20150791
Fisher, Christine14-1465
Phase I, Open-Label, Dose-Escalation Study of the Safety and Pharmacokinetics of MOXR0916 Administered Intravenously as a Single Agent to Patients with Locally Advanced or Metastatic Solid Tumors. Sponsor Protocol No. GO29313. WIRB Protocol No. 20141118
Camidge, David14-1476
A Phase 1 Dose Escalation and Phase 2 Randomized Double-Blind Study of Veliparib in Combination with Carboplatin and Etoposide as a Therapy of Treatment-Naïve Extensive Stage Disease Small Cell Lung Cancer. Sponsor Protocol No. M14-361. WIRB Protocol No. 20142537
Camidge, David14-1489
A Randomized, Open-Label, Multicenter Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Co-Administration of ABT-493 and ABT-530 With and Without RBV in Subjects With Chronic Hepatitis C Virus (HCV) Genotype 2 or Genotype 3 Infection (SURVEYOR-II). Sponsor Protocol No. M14-868. WIRB Protocol No. 20141974
Everson, Greg14-1494
A Phase 2B Prospective, Randomized, Double-blinded, Placebo-controlled Clinical Study Demonstrating the Efficacy and Safety of Rebiotix RBX2660 (microbiota suspension) for the Treatment of Recurrent Clostridium difficile Infection. Sponsor Protocol No. 2014-01. WIRB Protocol No. 20141261
Freeman, Stephen14-1538
A PHASE I, OPEN-LABEL STUDY EVALUATING THE SAFETY AND TOLERABILITY OF ESCALATING DOSES OF DLYE5953A IN PATIENTS WITH REFRACTORY SOLID TUMORS Sponsor Protocol No. GO29146 WIRB Protocol No. 20140268
Weekes, Colin14-1551
TIGER 1: A Randomized, Open-Label, Phase II Study of CO-1686 or Erlotinib as First-Line Treatment of Patients with EGFR-Mutant Advanced Non-Small Cell Lung Cancer (NSCLC) Sponsor Protocol No. CO-1686-022 WIRB Protocol No. 20142085
Camidge, David14-1569
An Open-Label, Multi-Center, 48-Week Study with a Concurrent Untreated Control Arm to Evaluate the Efficacy and Safety of Eteplirsen in Duchenne Muscular Dystrophy. Sponsor Protocol No. 4658-301-a1. WIRB Protocol No. 20141230
Parsons, Julie14-1629
Multicenter, open-label, randomized, controlled phase III clinical study of the efficacy and safety of photodynamic therapy using porfimer sodium for injection as treatment for unresectable advanced perihilar cholangiocarcinoma Sponsor Protocol No. PIN-PHO1201 WIRB Protocol No. 20140456
Shah, Raj14-1650
A Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter, Multiregional, One Year Study to Assess the Efficacy and Safety of Twice Daily Oral Rifaximin Delayed Release Tablets for Induction of Clinical Remission with Endoscopic Response at 16 Weeks followed by Clinical and Endoscopic Remission at 52 Weeks in Subjects with Active Moderate Crohn's Disease. Sponsor Protocol No. RECD3125. WIRB Protocol No. 20141667
Gerich, Mark14-1659
A Comparison of Soy Protein versus Soy-Dairy Protein-blend Containing Foods in the Colorado Diet for Weight loss and Maintenance. WIRB Protocol No. 20150081
Hill, James14-1666
A Multicenter, Randomized, Open-Label Phase 2b Study to Investigate the Efficacy and Safety of Aldoxorubicin Compared to Topotecan in Subjects with Metastatic Small Cell Lung Cancer Who Either Relapsed or Were Refractory to Prior Chemotherapy Sponsor Protocol No. ALDOXORUBICIN-P2-SCLC-01 WIRB Protocol No. 20141373
Doebele, Robert14-1673


Contact Us

Building 500 - 13001 E. 17th Place, Campus Box C290, Aurora, CO 80045

Learn more